UTILIUM SIGNED
Unraveling The Immune Landscape In Uveal Melanoma
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0UTILIUM project word cloud
Explore the words cloud of the UTILIUM project. It provides you a very rough idea of what is the project "UTILIUM" about.
Project "UTILIUM" data sheet
The following table provides information about the project.
| Coordinator |
REGION HOVEDSTADEN
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Total cost | 200˙194 € |
| EC max contribution | 200˙194 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2017 |
| Funding Scheme | MSCA-IF-EF-SE |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-09-01 to 2020-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | REGION HOVEDSTADEN | DK (HILLEROD) | coordinator | 200˙194.00 |
Map
Project objective
Cancer Immunotherapy is the latest breakthrough in the fight against cancer, especially with the successes of checkpoint inhibitors. However, numerous tumors appear non-responsive, including uveal melanoma (UM) despite its shared cellular origin with cutaneous melanoma. In this project, I propose to study the immune landscape of UM and explore strategies to overcome mechanisms detrimental to the antitumor immune response. I will employ highly innovative technologies from the fields of genomics, immunology and bioinformatics to explore the tumor microenvironment. Gene expression profiles of UM metastases and neoantigen presentation will be obtained by RNA sequencing. The functional expression of multiple immune markers will be analyzed by cutting-edge multispectral immunohistochemistry to determine immune cell subset presence in a qualitative and quantitative manner. The obtained knowledge will subsequently be used to test and improve reactivity of tumor-infiltrating lymphocytes in an autologous model. These experiments require optimal expansion of tumor-infiltrating T cells, which is highly developed at the laboratory of prof. Svane at the Center for Cancer Immune Therapy at the Herlev Hospital in Copenhagen, Denmark. I expect that this project will provide a more complete overview of the immune landscape of UM and reveal important mechanisms underlying immune suppression in UM. The findings of this project could pave the way to the clinical development of successful immunotherapeutic strategies for the treatment of UM and potentially other tumor types resistant to immune checkpoint inhibitors. Finally, this project will improve my laboratory and leadership skills, greatly improving my chances of achieving the next goal in my career: a permanent position as an Medical Oncologist with my own lab-based group in the expanding field of Cancer Immunotherapy to accelerate the application of translational research into the clinic.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Bol, Ellebaek, Hoejberg, Bagger, Larsen, Klausen, Køhler, Schmidt, Bastholt, Kiilgaard, Donia, Svane Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma published pages: 1489, ISSN: 2072-6694, DOI: 10.3390/cancers11101489 |
Cancers 11/10 | 2019-10-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UTILIUM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "UTILIUM" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.1.3.2.)
MacMeninges (2019)
Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging
Read More